IV adenosine

PreclinicalSmall molecule

IV adenosine is one of 6 small molecule programs targeting Supraventricular tachycardia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Supraventricular TachycardiaActive, not recruiting

Supraventricular TachycardiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Supraventricular Tachycardia

#DrugCompanyPhaseTrials

Cordarone

WWyeth-Lederle Vaccines

Adenocard

1 3

Tambocor

AAlvogen Korea

Preclinical

1 4

Calan

VVal Adams

Preclinical

1 5

IV adenosine

UUniversity of Iowa

Preclinical

1 6

Dexmedetomidine, Midazolam

NNational Taiwan University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Supraventricular Tachycardia (SVT)

NCT07086560

Clinical

Trials by Indication[1]

Supraventricular Tachycardia (SVT)1 trial

PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department: PERVADE-ED Study

Recruiting·UUniversity of Iowa··NCT07086560·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IV adenosine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV adenosine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV adenosine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Iowa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Iowa

IV adenosine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Supraventricular Tachycardia (SVT)1 trial

References

Drug Info

Quick Facts

Related News